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Abstract
Background—An alternate HIV testing algorithm has been proposed which includes a fourth-
generation immunoassay followed by an HIV-1/HIV-2 antibody differentiation supplemental test 
for reactive specimens and a nucleic acid test (NAT) for specimens with discordant results.
Objective—To evaluate the performance of five rapid tests (Alere Clearview, Bio-Rad 
Multispot, OraSure OraQuick, MedMira Reveal, and Trinity Biotech Unigold) as the supplemental 
antibody assay in the algorithm.
Study Design—A total of 3273 serum and plasma specimens that were third- generation 
immunoassay repeatedly reactive and Western blot (WB) negative or indeterminate were tested 
with rapid tests and NAT. Specimens were classified by NAT 1) HIV-1 infected (NAT-reactive; 
n=184, 5.6%), 2) HIV-status unknown (NAT nonreactive; n=3078, 94.2%) or by Multispot 3) 
HIV-2 positive (n=5), 4) HIV-1 and HIV-2 positive (n=6). Excluding HIV-2 positive specimens, 
we calculated the proportion of reactive rapid tests among specimens with reactive and 
nonreactive NAT.
Results—The proportion of infected specimens with reactive rapid test results and negative or 
indeterminate WB ranged from 30.4% (56) to 47.8% (88) depending on the rapid test. From 1% to 
2% of NAT-negative specimens had reactive rapid test results.
Conclusions—In these diagnostically challenging specimens, all rapid tests identified infections 
that were missed by the Western blot, but only one FDA-approved rapid test could differentiate 
HIV-1 from HIV-2. Regardless of which rapid test is used as a supplemental test in the alternative 
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algorithm, false-positive algorithm results (i.e., reactive screening and rapid test in uninfected 
person) may occur, which will need to be resolved during the baseline medical evaluation.
Background
Although HIV-1 Western blots have historically been used as supplemental tests to confirm 
HIV infection in specimens with repeatedly reactive immunoassay results, they detect HIV 
infection weeks later than most currently available screening immunoassays, 1–4 are time-
consuming, 5 may produce indeterminate results in persons who are infected or 
uninfected, 6, 7 and misclassify the majority of HIV-2 infections as HIV-1.8, 9 In response to 
the limitations of the Western blot, an alternate testing algorithm has been proposed by the 
Centers for Disease Control and Prevention (CDC) and the Association of Public Health 
Laboratories (APHL) which uses a fourth-generation antigen/antibody screening 
immunoassay (IA) and supplemental tests that include an HIV-1/HIV-2 antibody 
differentiation test and an HIV-1 nucleic acid test (NAT) (Figure 1).5, 10 If the specimen is 
repeatedly reactive using the fourth-generation IA and the supplemental antibody test is 
reactive for HIV-1 and/or HIV-2 antibodies, the person is considered to have established 
HIV-1 or HIV-2 infection. If the supplemental antibody test is negative, an HIV-1 RNA 
NAT is performed and, if positive, that person is considered to have acute HIV-1 infection. 
As recommended in the Department of Health and Human Services antiretroviral treatment 
guidelines, persons who test positive for HIV should receive a baseline medical evaluation 
that includes laboratory tests .11
Although an antigen/antibody IA is recommended as the screening assay for this new HIV 
diagnostic algorithm, third-generation immunoassays are still used in many laboratories.12 
The use of a third-generation IA is given as an alternative screening IA in the proposed 
algorithm and its performance in the algorithm has been evaluated.1314, 154 Most FDA-
approved rapid tests can detect both HIV-1 and HIV-2, but only the Multispot HIV-1/HIV-2 
Rapid Test (BioRad Laboratories, Redmond, WA) is FDA-approved as a differentiation test 
for supplemental testing. Although the proposed algorithm provides alternate FDA-approved 
antibody supplemental tests in place of the differentiation test in the algorithm (e.g., HIV-1 
Western blot and immunofluorescence assay),13 the performance of other rapid tests has not 
been assessed and could inform testing guidance.
Objective
To evaluate the performance of five rapid antibody tests as supplemental assays in the 
alternate HIV testing algorithm using diagnostically challenging specimens that were 
repeatedly reactive with an initial third generation immunoassay, but not Western blot 
positive.
Study Design
From January 1, 2009 to September 9, 2010, over 6 million HIV tests were conducted at 
Quest Diagnostics laboratory facilities in the United States. The HIV prevalence in this 
population is estimated to be 1.3% among non-pregnant persons. 16 The company identified 
candidate specimens as all serum or plasma specimens tested in their United States 
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laboratories with repeatedly reactive third-generation immunoassay results (GS HIV-1/
HIV-2 Plus O, BioRad Laboratories, Redmond, WA) and negative or indeterminate Western 
blot results (GS HIV-1 Western blot, BioRad Laboratories, Redmond, WA). These 
specimens were sent to a central laboratory where links to personally identifying 
information were removed.
Specimens with sufficient volume were tested with 5 FDA-approved rapid antibody tests 
according to package insert instructions: Clearview HIV-1/2 StatPak (Clearview, Alere, 
Orlando, FL), Multispot HIV-1/HIV-2 Rapid Test (Multispot, BioRad Laboratories, 
Redmond, WA), OraQuick Advance Rapid HIV-1/2 Antibody Test (OraQuick, Orasure 
Technologies, Bethlehem, PA), Reveal G3 Rapid HIV-1 Antibody Test (Reveal, MedMira 
Laboratories, Halifax, Nova Scotia, Canada), and Uni-Gold Recombigen HIV Test (Uni-
Gold, Trinity BioTech, Wicklow, Ireland). Four rapid tests are FDA-approved for use with 
serum or plasma. OraQuick, which is approved for use on plasma, was also used with serum. 
Reveal and Uni-gold are FDA-approved to detect HIV-1 only. Clearview and OraQuick can 
detect HIV-1 and HIV-2, and Multispot can detect and differentiate HIV-1 and HIV-2.
All specimens with sufficient volume were tested with the APTIMA HIV-1 RNA 
Qualitative Assay (APTIMA, GEN-PROBE, San Diego, CA), which is FDA approved for 
use on serum and plasma. Specimens with negative results on all rapid tests were tested with 
APTIMA in pools of 16 at the Florida Bureau of Laboratories, 17 with the exception that 
reactive pools were repeated. Specimens in pools that were non-reactive initially or on 
repeat testing were considered to be APTIMA negative. Pools testing repeatedly reactive on 
the APTIMA test were deconstructed, and specimens were tested individually with 
APTIMA. Specimens with one or more positive rapid test were tested individually with 
APTIMA at the CDC laboratory using 100μL of serum or plasma supplemented with 400μL 
of IA and APTIMA-negative plasma. It is possible that some specimens may not have been 
handled according to APTIMA package insert specifications with regard to holding 
temperatures or freeze-thaw cycles because they were not originally collected with the intent 
of being tested with that assay.
Specimens were categorized by HIV infection status as: 1) HIV-1 infected (reactive by 
APTIMA; n=184, 5.6%) ; 2) HIV status unknown (negative APTIMA; n=3078, 94.0%) ; 3) 
HIV-2 antibody positive (HIV-1 antibody negative and HIV-2 antibody reactive using 
Multispot, regardless of APTIMA results; n=5,0.2%) ; and 4) HIV-infected, undifferentiated 
(HIV-1 and HIV-2 antibody reactive using Multispot, regardless of APTIMA results; n=6, 
0.2%). Due to volume constraints, specimens with undifferentiated results did not undergo 
testing according to the Multispot dilution protocol.
We excluded the specimens with reactive HIV-2 results and undifferentiated results from 
analysis. Among the HIV-infected specimens, for each rapid test, we calculated the number 
and proportion of specimens with reactive rapid results stratified by Western blot results. 
Among those with negative APTIMA results, for each rapid test, we calculated the number 
and proportion of specimens with positive rapid test results by Western blot results. We also 
calculated the proportion with negative results on rapid tests. Statistical analysis was 
conducted using SAS version 9.3 (Cary, NC).
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Of the 6934 specimens with IA-repeatedly reactive and Western blot negative or 
indeterminate results identified during the study period, funding permitted the acquisition of 
3999 specimens (57.7%) with sufficient volume for testing with the five rapid tests. Of 
those, 3273 (81.8%) had sufficient volume to conduct APTIMA and were included in further 
analyses. Among the 726 specimens not included in analyses, 659 had insufficient volume 
for APTIMA testing, 60 had reactive pooled APTIMA testing, but insufficient volume for 
individual testing, and 7 had an invalid pooled result with insufficient volume for repeat 
testing. Among the specimens not included in the analyses (n=726), the number with 
reactive rapid tests ranged from 13 (1.8%) (Reveal) to 28 (3.9%) (Multispot).
Of the 3273 total specimens that were GS IA repeatedly reactive and Western blot negative 
or indeterminate, 184 (5.6%) were HIV-1 infected based on reactive APTIMA results. Of 
these, 93 (50.5%) had an indeterminate Western blot result. Between 40 (43.0%) and 68 
(73.1%) of these were detected by at least one rapid test, and 60 (64.5%) were detected by 
more than one rapid test (Table 1). There were 91 (49.5%) infected specimens with a 
negative Western blot result. Between 14 (15.4%) and 20 (22.0%) of these were positive on 
at least one rapid test, and 18 (19.8%) were positive on more than one rapid test. In most 
cases, the 95% confidence intervals for the proportion of infections identified by a rapid test 
overlapped with that of the other rapid tests. In addition, Multispot identified 5 (0.2%) 
specimens with HIV-2 antibodies and 6 (0.2%) specimens with both HIV-1 and HIV-2 
antibodies.
There were 3078 (94.0%) specimens with non-reactive APTIMA results (Table 2), 735 
(23.9%) of which had an indeterminate Western blot. Between 16 (2.2%) and 37 (5.0%) of 
these were positive by a rapid test, and 33 (4.5%) were positive by more than one rapid test. 
There were 2343 (76.1%) specimens with negative Western blot results. Between 9 (0.4%) 
and 26 (1.1%) of these were positive by a rapid test, and 11 (0.5%) were positive by more 
than one rapid test. The proportion of APTIMA-negative specimens with negative rapid test 
results ranged from 98.0% to 99.0%, and the 95% confidence intervals of these proportions 
overlapped for most tests.
Discussion
In this evaluation of 3273 specimens that were third-generation HIV 1/2 IA reactive but 
Western blot negative or indeterminate, one-third to one-half of specimens with detectable 
RNA were classified as antibody-positive by the rapid tests. When the alternate HIV 
diagnostic algorithm is used and infections are missed by rapid supplemental tests, they are 
likely to be detected by an HIV-1 NAT which can identify the presence of viral RNA within 
two weeks of exposure.3, 4, 15 These specimens from HIV-infected individuals, which were 
not detected by Western blot, likely represent early infections. Other investigations have 
shown an even lower proportion of early infections detected by rapid tests. 18, 19 It is 
unknown whether persons misclassified as uninfected based on Western blot ultimately 
learned of their infection, which highlights the need for the alternate algorithm.
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Using the alternate algorithm,5 specimens that are reactive using the screening IA, non-
reactive using the rapid antibody test, and reactive by a NAT are flagged as early infections. 
There is utility in following the highly sensitivity initial IA with an assay that is less 
sensitive, such as a rapid test, so that early infections can be identified as such. Persons in 
the early stage of infection are likely to have high viral loads and, thus, pose a greater 
likelihood of disease transmission.20–22 Maximizing the public health impact of identifying 
early infections requires a timely response to link persons with care, treatment and partner 
services.23 Identifying early infections requires that persons present to testing venues shortly 
after an exposure event, which may necessitate education about the window period of new 
tests in communities impacted by HIV.23
Only one FDA-approved rapid HIV test, Multispot, distinguishes HIV-1 from HIV-2 and it 
captured 5 potential HIV-2 infections. It has been validated to perform well in the proposed 
algorithm, and it had the highest sensitivity among the rapid tests evaluated.4, 14, 15 
Although HIV-2 infections are rare in the United States,24 identifying them is important 
because they do not respond to non-nucleoside reverse transcriptase inhibitors and some 
protease inhibitors that are used as first-line antiretroviral treatment for HIV-1.25, 26 With 
wider implementation and use of the algorithm, increases in the number of HIV-2 cases 
detected in the United States might be observed.
Over 90% of the specimens analyzed had negative HIV-1 RNA APTIMA results. Many may 
be from uninfected individuals (i.e., a false positive HIV-1/2 antibody screening test result 
with negative rapid and NAT results). Based on the broader population of 6 million 
specimens, the specificity given in the package insert for the GS IA would predict that 6600 
specimens would be false-positive on this screening test. This number is close to the 6934 
total specimens identified as third-generation repeatedly reactive and Western blot negative 
or indeterminate, once those that were infected were removed. Assuming that all APTIMA 
non-reactive specimens were uninfected, the rapid test specificity would range from 98 to 
99%, and Multispot would have been concurrently false-positive with the screening test on 
more specimens than the other rapid tests. In two studies, Multispot specificity was 99.4%, 
an estimate which is higher than in this study because they did not include IA-reactive 
specimens. 14, 27 Those studies also showed Multispot specificity to be slightly lower than 
that for other rapid tests evaluated. It is conceivable that more cross-reactivity occurred 
between the GS screening IA and Multispot than other rapid tests because the tests are 
produced by the same manufacturer, and may use some of the same antigens. In other 
studies, concordant false positives between a GS screening IA and Multispot were rare.15, 28 
If concordant false-positive screening and supplemental rapid test results occur with the 
alternate algorithm, persons will have negative nucleic acid test results following their 
baseline evaluation in care 11 and will require further diagnostic testing. The false positive 
rate of HIV-1 Western blot in blood donors, based on a negative NAT result, was 4.8%, 
which is higher than the observed false-positive rate for any of the rapid tests evaluated 
here.29
One limitation of this study is that some of the specimens with negative APTIMA results 
might be from infected individuals, particularly those exhibiting viral bands on the Western 
blot and more than one reactive rapid test, but follow-up specimens were not available. 
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Occasional false-negative NAT results have been observed in HIV antibody-positive 
specimens.3, 17 Those with infections detected by the third-generation immunoassay but not 
APTIMA may have had this result due to antiretroviral use, dilution of specimens, specimen 
handling30 or because serum samples, which constituted most of this specimen set, have 
reduced RNA relative to plasma samples.31 An additional study limitation is that some 
APTIMA-reactive specimens could have been cross- contaminated during handling, 
especially those that simultaneously exhibited low APTIMA signal to cut-off values and 
rapid test non-reactivity (up to 7% of those classified as infected). If true, the rapid-test 
sensitivity determinations presented here would be underestimates.
In conclusion, although all of the rapid tests identified infections that were missed by the 
Western blot, only one FDA-approved rapid test differentiates HIV-1 from HIV-2. 
Regardless of which rapid test is used, false-positive algorithm results may occur, which will 
need to be resolved during the baseline medical evaluation. For individuals with established 
HIV infections that will be resolved by the algorithm without NAT testing, the time to test 
result receipt should be reduced when a rapid test is used as a supplemental test in place of a 
Western blot. Although currently available FDA-approved rapid tests are not as sensitive as 
third- or fourth-generation IA for the detection of early HIV infection, they function as well 
as or better than the Western Blot for detecting early HIV infection.3,4 Their use as a 
supplemental test in the alternate algorithm in conjunction with a nucleic acid test will allow 
healthcare personnel to more effectively identify recently infected individuals and to provide 
a timelier response to interrupt further transmission.
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Table 1
HIV rapid test results among specimens with repeatedly reactive HIV 1/2 IA, negative or indeterminate 
Western blot, and positive APTIMA results
Rapid HIV Test Indeterminate WB 
(n=93) and positive RT N 
(%)
Negative WB (n=91) 





Proportion HIV-infected with 
positive RTb (95% Confidence 
Interval)
Clearview 48 (51.6%) 16 (17.6%) 64 34.8% (27.9%–42.1%)
Multispot 68 (73.1%) 20 (22.0%) 88 47.8% (40.4%–55.3%)
OraQuick 44 (47.3%) 14 (15.4%) 58 31.5% (24.9%–38.8%)
Reveal 40 (43.0%) 16 (17.6%) 56 30.4% (23.9%–37.6%)
Unigold 59 (63.4%) 20 (22.0%) 79 42.9% (35.7%–50.4%)
>1 reactive rapid test 60 (64.5%) 18 (19.8%) n/a not applicable
WB=Western blot; RT=rapid test
a
HIV-infected=GS IA repeatedly reactive and APTIMA (nucleic acid test)-positive
b
Specimens with reactive rapid test results/# GS IA repeatedly reactive and APTIMA positive specimens
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Table 2
HIV rapid test results among specimens with repeatedly reactive HIV 1/2 IA, negative or indeterminate 
Western blot, and negative APTIMA results
Rapid HIV test Indeterminate WB, 
negative APTIMA 





positive RT N (%)
Total with positive 
RT and negative 
APTIMA (n=3078)
Proportion with negative 
APTIMA and negative RT (95% 
Confidence Interval)
Clearview 23 (3.1%) 10 (0.4%) 33 98.9% (98.5%–99.3%)
Multispot 37 (5.0%) 26 (1.1%) 63 98.0% (97.4%–98.4%)
Oraquick 26 (3.5%) 10 (0.4%) 36 98.8% (98.4%–99.2%)
Reveal 16 (2.2%) 14 (0.6%) 30 99.0%a (98.6%–99.3%)
Unigold 29 (4.0%) 9 (0.4%) 38 98.8% (98.3%–99.1%)
>1 reactive rapid test 33 (4.5%) 11 (0.5%) n/a not applicable
WB=Western blot; RT=Rapid test
a
7 specimens had invalid results with Reveal, and were not included in analyses.
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